Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.51 |
| ▸ | BRAF | P15056 | 9/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867635 | 0.90 | KIT (0.52) | KITBRAFKDRHDAC1PDGFRA | |
| SCHEMBL3871155 | 0.89 | KIT (0.54) | KITBRAFKDRFLT1 | |
| SCHEMBL1488581 | 0.86 | KIT (0.44) | KITBRAFKDRHDAC1NPC1 | |
| SCHEMBL3867862 | 0.82 | KIT (0.53) | KITBRAFKDRHDAC1NPC1 | |
| SCHEMBL3871151 | 0.78 | KIT (0.56) | KITBRAFKDRFLT1 | |
| SCHEMBL1488924 | 0.76 | KIT (0.46) | KITBRAFKDRFLT1 | |
| SCHEMBL4035003 | 0.74 | KDR (0.45) | KITBRAFKDRNPC1RAB9A | |
| SCHEMBL4037276 | 0.74 | KDR (0.43) | KITBRAFKDRPDGFRANPC1 | |
| SCHEMBL4035005 | 0.73 | KDR (0.45) | KITBRAFKDRNPC1RAB9A | |
| SCHEMBL4037293 | 0.73 | KIT (0.51) | KITBRAFKDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | claimed |
| EP-1807415-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | claimed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | claimed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | claimed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | KIT 83/4885BRAF 495/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.